天津科学技术出版社

肠道菌群代谢产物通过肠-肺轴调控肺癌微环境的机制与研究进展

胡子轩 1,2,丁帝凯 1,王建芳 2,刘红雨 2,陈军 1,2 *
作者信息
  1. 1 天津医科大学总医院肺部肿瘤外科,天津 300052
  2. 2 天津医科大学总医院肺癌研究所,天津 300052
*通信作者

摘要

肺癌是全球癌症相关死亡的首要原因,其发生、发展进程与宿主微环境的动态调控机制存在密切关联。 近年来,肠道菌群作为人体“第二基因组“,借助“肠-肺轴”发挥调控作用,其在肺癌进展过程中的核心作用备受学界关注。 系统梳理并总结肠道菌群及其代谢产物(如短链脂肪酸、多胺、色氨酸代谢物等)通过循环系统实现远距离调控肺癌肿瘤微环境(TME)的关键分子机制,重点阐述肠道菌群失调状态(尤以抗生素使用诱导的菌群紊乱为典型)会促使肺炎克雷伯菌等机会致病菌异常增殖,同时抑制阿克曼菌等有益菌的定植与生长,进而导致丁酸等具备免疫调节功能的关键代谢产物生成减少。上述级联反应最终会通过调控肿瘤相关巨噬细胞(TAMs)极化方向、影响T淋巴细胞免疫功能,以及改变免疫检查点抑制剂(ICIs)的疗效,进一步推动肺癌的发生与进展。 同时,针对性探讨基于肠道菌群的靶向干预策略,包括益生菌补充、粪菌移植(FMT)、特异性代谢产物外源性补充等方式,在肺癌临床治疗中的潜在应用价值。最后,系统分析当前该领域研究存在的局限性,并对未来研究方向进行展望,旨在为肺癌精准免疫治疗的优化与突破提供全新的理论思路与研究方向。

Mechanism and research progress of gut microbiota metabolites regulating the lung cancer microenvironment through the gut-lung axis

Zixuan HU 1,2, Dikai DING 1, Jianfang WANG 2, Hongyu LIU 2, Jun CHEN 1,2 *
Author Information
  1. 1 Department of Pulmonary Tumor Surgery, Tianjin Medical University General Hospital,Tianjin 300052, China
  2. 2 Institute of Lung Cancer, Tianjin Medical University General Hospital, Tianjin 300052, China
*Corresponding author

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide, and its occurrence and development are closely related to the dynamic regulatory mechanisms of the host microenvironment. In recent years, the gut microbiota, as the " second genome" of the human body, plays a regulatory role through the "gut-lung axis" , and its core role in the progression of lung cancer has attracted much attention from the academic community. This review systematically summarizes the key molecular mechanisms by which the gut microbiota and its metabolites (such as short chain fatty acids, polyamines, tryptophan metabolites, etc. ) achieve remote regulation of the lung cancer tumor microenvironment (TME) through the circulatory system. Emphasis is placed on elucidating the dysbiosis of the gut microbiota (especially the dysbiosis induced by antibiotic use), which promotes abnormal proliferation of opportunistic pathogenic bacteria such as Klebsiella pneumoniae, while inhibiting the colonization and growth of beneficial bacteria such as Akkermansia, leading to a reduction in the production of key metabolites with immune regulatory functions such as butyric acid. The above cascade reactions will ultimately promote the occurrence and progression of lung cancer by regulating the polarization direction of tumor associated macrophages (TAMs), affecting the immune function of T lymphocytes, and altering the therapeutic efficacy of immune checkpoint inhibitors (ICIs). Meanwhile, targeted interventions based on gut microbiota, including probiotic supplementation, fecal microbiota transplantation (FMT), and exogenous supplementation of specific metabolites, are being explored for their potential application value in the clinical treatment of lung cancer. Finally, systematically analyze the limitations of current research in this field and looks forward to future research directions, aiming to provide new theoretical ideas and research directions for the optimization and breakthrough of precision immunotherapy for lung cancer.

再生医学研究 Copyright © 2026. All Rights Reserved